Adding Hydroxycarbamide to Aspirin of Little Benefit to Certain Older Patients with Essential Thrombocythemia

A recent open-label, randomized trial of patients with essential thrombocythemia age 40-59 without high-risk features or extreme thrombocytosis found that the cytoreductive therapy combination of hydroxycarbamide plus aspirin did not reduce vascular events, myelofibrotic transformation, or leukemic transformation compared with aspirin alone.

 Oncology Learning Network

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.